All In Biotech

Drug Trial Radar · NCT04889430

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

A Multicenter, Single-arm, Open Label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult aHUS Patients Who Are Naive to Complement Inhibitor Therapy

Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

34

Actual

Start

Jan 17, 2022

Primary completion

Apr 11, 2026

Study completion Apr 11, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.

Conditions

  • Atypical Hemolytic Uremic Syndrome

Interventions

  • IptacopanDrug

    Iptacopan 200mg twice daily oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with complete TMA response without the use of PE/PI and anti-C5 antibodyTime frame: 26 weeks of study treatment
  2. Long term safety and efficacy evaluationsTime frame: 52 weeks of study treatment

Locations

36 sites in 8 countries. Site status is shown where the registry gives one.

  • USC Norris Cancer Center

    Los Angeles, California

  • Univ of California at Los Angeles

    Los Angeles, California

  • Univ Cali Irvine ALS Neuromuscular

    Orange, California

  • Univ of California at Sacramento

    Sacramento, California

  • Harbor-UCLA Medical Center .

    Torrance, California

  • Georgetown University Lombardi Cancer Center

    Washington D.C., District of Columbia

  • University Of Miami

    Miami, Florida

  • University of Minnesota

    Minneapolis, Minnesota

  • Montefiore Medical Center .

    The Bronx, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Duke University Medical Center

    Durham, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Comprehensive Transplant Ctr at OSU

    Columbus, Ohio

  • UT Southwestern Medical Center

    Dallas, Texas

  • Virginia Commonwealth University

    Richmond, Virginia

  • Novartis Investigative Site

    Rio de Janeiro, Brazil

  • Novartis Investigative Site

    Salvador, Brazil

  • Novartis Investigative Site

    Fortaleza, Ceará, Brazil

  • Novartis Investigative Site

    Brasília, Federal District, Brazil

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, Brazil

  • Novartis Investigative Site

    Recife, Pernambuco, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Ostrava, Poruba, Czechia

  • Novartis Investigative Site

    Nagpur, Maharashtra, India

  • Novartis Investigative Site

    Pune, Maharashtra, India

  • Novartis Investigative Site

    Chandigarh, Punjab, India

  • Novartis Investigative Site

    Lucknow, Uttar Pradesh, India

  • Novartis Investigative Site

    Iruma-gun, Saitama, Japan

  • Novartis Investigative Site

    Seoul, Seoul, South Korea

  • Novartis Investigative Site

    Taichung, Taiwan

  • Novartis Investigative Site

    Taoyuan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.